You have free access to this content

Cancer

Cover image for Cancer

1 January 2010

Volume 116, Issue 1

Pages 1–260

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorial
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Correspondence
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
      New in the seventh edition (page 3)

      Carrie Printz

      Version of Record online: 11 JAN 2010 | DOI: 10.1002/cncr.24849

  2. Editorial

    1. Top of page
    2. CancerScope
    3. Editorial
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Correspondence
    1. You have free access to this content
      Where does the combination of sorafenib and interferon in renal cell carcinoma stand? (pages 4–7)

      Keith T. Flaherty

      Version of Record online: 4 NOV 2009 | DOI: 10.1002/cncr.24688

      Sorafenib can be combined safely with interferon, but the results of a recent randomized, phase 2 trial cast doubt on the value of further evaluating this combination. The renal cell carcinoma field continues to wrestle with the value of combining “targeted” therapies with cytokines.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorial
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk (pages 8–19)

      William D. Dupont, Joan P. Breyer, Kevin M. Bradley, Peggy A. Schuyler, W. Dale Plummer, Melinda E. Sanders, David L. Page and Jeffrey R. Smith

      Version of Record online: 4 NOV 2009 | DOI: 10.1002/cncr.24702

      • original image
      • original image

      Protein phosphatase 2A (PP2A) is a major cellular phosphatase and plays key regulatory roles in growth, differentiation, and apoptosis. In this study, the authors identified significant risk and protective haplotypes of the PP2A structural regulatory subunit A α isoform (PPP2R1A). Women who had both the PPP2R1A risk haplotype and a history of proliferative breast disease had a further elevation in breast cancer risk.

      Corrected by:

      Erratum: Erratum

      Vol. 116, Issue 7, 1840, Version of Record online: 8 FEB 2010

  4. Original Article

    1. Top of page
    2. CancerScope
    3. Editorial
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Correspondence
    1. Disease Site

      Endocrine Disease
      You have free access to this content
      Treatment patterns of aging Americans with differentiated thyroid cancer (pages 20–30)

      Henry S. Park, Sanziana A. Roman and Julie Ann Sosa

      Version of Record online: 11 NOV 2009 | DOI: 10.1002/cncr.24717

      • original image
      • original image
      • original image

      Using the Surveillance, Epidemiology, and End Results database, the authors demonstrated that elderly patients with differentiated thyroid cancer received less aggressive surgical and radioactive iodine (RAI) treatment than younger patients despite having more advanced disease. The results also demonstrated that both surgical and RAI treatment are associated with improved survival among elderly patients.

  5. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorial
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Correspondence
    1. Disease Site

      Endocrine Disease
      You have free access to this content
      Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer (pages 31–40)

      Martin A. Walter, Christian Meier, Tanja Radimerski, Fabienne Iten, Marius Kränzlin, Jan Müller-Brand, Jan Willem B. de Groot, Ido P. Kema, Thera P. Links and Beat Müller

      Version of Record online: 4 NOV 2009 | DOI: 10.1002/cncr.24738

      • original image
      • original image
      • original image
      • original image
      • original image

      The results of the current study demonstrate an independent predictive value of the calcitonin precursor procalcitonin in medullary thyroid cancer. The procalcitonin:calcitonin ratio might represent a novel and easily accessible tool leading to more personalized diagnostic and therapeutic strategies for patients with medullary thyroid cancer.

    2. Gastrointestinal Disease
      You have free access to this content
      Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer (pages 41–49)

      Caiping Gao, Zhiyu Zhang, Wenzhong Liu, Shudong Xiao, Weiqi Gu and Hong Lu

      Version of Record online: 4 NOV 2009 | DOI: 10.1002/cncr.24743

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Helicobacter pylori infection resulted in decreased microRNA-218 (miR-218) expression. In the current study, reduced miR-218 expression was associated with high nuclear factor κB activation in gastric cancer.

    3. Genitourinary Disease
      You have free access to this content
      Racial differences in treatment and outcomes among patients with early stage bladder cancer (pages 50–56)

      Brent K. Hollenbeck, Rodney L. Dunn, Zaojun Ye, John M. Hollingsworth, Cheryl T. Lee and John D. Birkmeyer

      Version of Record online: 28 OCT 2009 | DOI: 10.1002/cncr.24701

      • original image

      Black patients with early stage (ie, superficial) bladder cancer fared worse in terms of overall survival compared with white patients. However, this disparity was not attributable to the intensity of the quality of the bladder cancer care delivered.

    4. You have free access to this content
      Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma : Clinical and biomarker analysis (pages 57–65)

      Eric Jonasch, Paul Corn, Lance C. Pagliaro, Carla L. Warneke, Marcella M. Johnson, Pheroze Tamboli, Chaan Ng, Ana Aparicio, Robynne G. Ashe, John J. Wright and Nizar M. Tannir

      Version of Record online: 27 OCT 2009 | DOI: 10.1002/cncr.24685

      Untreated patients with metastatic renal cell carcinoma had similar outcomes when treated either with sorafenib alone or with sorafenib plus low-dose interferon. Activated protein kinase B may be a predictive biomarker of sorafenib resistance.

    5. You have free access to this content
      Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer (pages 66–76)

      Shahana Majid, Altaf A. Dar, Varahram Shahryari, Hiroshi Hirata, Ardalan Ahmad, Sharanjot Saini, Yuichiro Tanaka, Angela V. Dahiya and Rajvir Dahiya

      Version of Record online: 2 NOV 2009 | DOI: 10.1002/cncr.24662

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Epigenetic silencing of tumor suppressor gene B-cell translocation gene 3 in prostate cancer can be reactivated by genistein induced promoter demethylation and active histone modification. Genistein being a natural, nontoxic, dietary isoflavone may be a novel, advantageous, therapeutic agent for treating prostate cancer.

    6. Head and Neck Disease
      You have free access to this content
      Prognostic value of quantitative p63 immunostaining in adenoid cystic carcinoma of salivary gland assessed by computerized image analysis (pages 77–83)

      Naomi Ramer, HaiShan Wu, Edmond Sabo, Yael Ramer, Patrick Emanuel, Lurmag Orta and David E. Burstein

      Version of Record online: 28 OCT 2009 | DOI: 10.1002/cncr.24657

      • original image
      • original image
      • original image
      • original image
      • original image

      The present study is the first to examine and establish a correlation of the extent of p63 expression with prognosis of adenoid cystic carcinoma. It is performable on routinely fixed and processed tissue and represents a useful algorithmic method of quantifying p63 immunostaining.

    7. Hematologic Malignancies
      You have free access to this content
      Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma (pages 84–92)

      Sikander Ailawadhi, Ahmed N. Abdelhalim, Lyudmyla Derby, Terry L. Mashtare, Kena C. Miller, Gregory E. Wilding, Ronald A. Alberico, Ronald Gottlieb, Donald L. Klippenstein, Kelvin Lee and Asher A. Chanan-Khan

      Version of Record online: 27 OCT 2009 | DOI: 10.1002/cncr.24704

      • original image
      • original image
      • original image
      • original image

      Magnetic resonance imaging of the bone marrow (BM-MRI) is a novel, noninvasive technique for assessing bone marrow involvement in multiple myeloma. The authors developed a semiquantitative BM-MRI staging system that correlates accurately with other conventional parameters of disease burden and can independently predict survival in patients with multiple myeloma at the time of initial diagnosis.

    8. You have free access to this content
      Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome (pages 93–97)

      Ali Al Ameri, Charles Koller, Hagop Kantarjian, Farhad Ravandi, Srdan Verstovsek, Gautam Borthakur, Sherry Pierce and Gloria Mattiuzzi

      Version of Record online: 27 OCT 2009 | DOI: 10.1002/cncr.24711

      • original image
      • original image

      Acute pulmonary failure during remission induction therapy is a serious complication in patients with acute myeloid leukemia. Early acute pulmonary failure remains a serious complication of remission induction therapy, which is often complicated by subsequent other organ failure and death.

    9. You have free access to this content
      Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia (pages 98–105)

      Hiroto Inaba, Clinton F. Stewart, Kristine R. Crews, Shengping Yang, Stanley Pounds, Ching-Hon Pui, Jeffrey E. Rubnitz, Bassem I. Razzouk and Raul C. Ribeiro

      Version of Record online: 2 NOV 2009 | DOI: 10.1002/cncr.24712

      • original image
      • original image

      The authors evaluated the maximum tolerated dose and dose-limiting toxicities of a 5-day course of cladribine followed by topotecan in pediatric patients with recurrent/refractory acute myeloid leukemia. This regimen offers a treatment alternative for patients, especially those who have received anthracycline-containing chemotherapy.

    10. You have free access to this content
      Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma : Results from a Multicenter Study (pages 106–114)

      Brad S. Kahl, Nancy L. Bartlett, John P. Leonard, Ling Chen, Kristen Ganjoo, Michael E. Williams, Myron S. Czuczman, K. Sue Robinson, Robin Joyce, Richard H. van der Jagt and Bruce D. Cheson

      Version of Record online: 4 NOV 2009 | DOI: 10.1002/cncr.24714

      • original image

      Single-agent bendamustine demonstrated encouraging efficacy and manageable toxicity in rituximab-refractory and chemotherapy-refractory patients with non-Hodgkin lymphoma.

    11. You have free access to this content
      Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy (pages 115–121)

      Yu Xuan Koo, Daniel S. W. Tan, Iain B. Tan, Miriam Tao, Wan Cheng Chow and Soon Thye Lim

      Version of Record online: 6 NOV 2009 | DOI: 10.1002/cncr.24742

      • original image

      All lymphoma patients in hepatitis B virus (HBV) endemic regions should be tested for HBV core antibody in addition to hepatitis B surface antigen. Low rate of HBV reactivation does not support the routine use of antiviral prophylaxis in patients with past HBV infection.

    12. Lung Disease
      You have free access to this content
      Modeling excess lung cancer risk among screened arm participants in the Mayo Lung Project (pages 122–131)

      Deborah L. Goldwasser and Marek Kimmel

      Version of Record online: 13 NOV 2009 | DOI: 10.1002/cncr.24722

      • original image
      • original image

      The authors fit a modified 2-stage clonal expansion (TSCE) model of excess lung cancer risk to long-term follow-up data from the Mayo Lung Project. The excess lung cancer risk observed among screening arm participants was found to be statistically significant with respect to the TSCE model framework, in part because of the incorporation of key risk correlates of age and screen frequency into the estimation framework.

    13. You have free access to this content
      Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer (pages 132–136)

      Dae Ho Lee, Sang-We Kim, Cheolwon Suh, Jung-Shin Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Im-Il Na, Jae Cheol Lee, Baek-Yeol Ryoo and Sung Hyun Yang

      Version of Record online: 10 NOV 2009 | DOI: 10.1002/cncr.24719

      • original image

      Belotecan, a new camptothecin analogue, when combined with cisplatin, demonstrated promising antitumor activity and a manageable toxicity profile in chemotherapy-naive patients with extensive-stage small cell lung cancer.

      Corrected by:

      Erratum: Erratum

      Vol. 116, Issue 2, 540, Version of Record online: 15 DEC 2009

    14. You have free access to this content
      Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer (pages 137–145)

      Xin Shelley Wang, Qiuling Shi, Charles Lu, Ethan M. Basch, Valen E. Johnson, Tito R. Mendoza, Gary M. Mobley and Charles S. Cleeland

      Version of Record online: 22 OCT 2009 | DOI: 10.1002/cncr.24703

      • original image

      Patient–reported symptom severity indicated increased risk for shorter survival in a group of patients with advanced nonsmall cell lung cancer who qualified for chemotherapy. These findings suggest that an individual patient's symptom severity scores, quickly obtainable in the clinic, might contribute clinically useful information for treatment planning for that patient.

    15. Melanoma
      You have free access to this content
      Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma (pages 146–154)

      Tim Eisen, Uwe Trefzer, Anne Hamilton, Peter Hersey, Michael Millward, Robert D. Knight, Jarl U. Jungnelius and John Glaspy

      Version of Record online: 27 OCT 2009 | DOI: 10.1002/cncr.24686

      • original image
      • original image
      • original image
      • original image

      An international, multicenter, randomized, double-blind, controlled study assessed the efficacy and safety of lenalidomide treatment in patients with refractory stage IV metastatic malignant melanoma. The study showed that treatment with lenalidomide (25 mg/d) has a manageable safety profile in patients with previously treated metastatic malignant melanoma, but provides no benefit in tumor response, time to progression, or overall survival in these patients.

    16. You have free access to this content
      A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma (pages 155–163)

      Evan M. Hersh, Steven J. O'Day, Antoni Ribas, Wolfram E. Samlowski, Michael S. Gordon, Deganit E. Shechter, Alicia A. Clawson and Rene Gonzalez

      Version of Record online: 28 OCT 2009 | DOI: 10.1002/cncr.24720

      • original image
      • original image
      • original image

      Treatment with nab-paclitaxel is active in both chemotherapy-naive and previously treated patients with metastatic malignant melanoma. Survival (pending confirmation in a randomized clinical trial) appeared to be longer than that reported in the literature for such patients.

    17. Neuro-Oncology
      You have free access to this content
      Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes (pages 164–176)

      Arabinda Das, Naren L. Banik and Swapan K. Ray

      Version of Record online: 5 NOV 2009 | DOI: 10.1002/cncr.24699

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Glioblastoma remains incurable with conventional chemotherapeutic agents. Plant-derived flavonoids induced apoptotic death in human glioblastoma T98G (mutant p53) and U87MG (wild-type p53) cells via activation of multiple mechanisms without affecting human normal astrocytes.

    18. Sarcoma
      You have free access to this content
      The symptom interval in children and adolescents with soft tissue sarcomas (pages 177–183)

      Andrea Ferrari, Rosalba Miceli, Michela Casanova, Cristina Meazza, Francesca Favini, Roberto Luksch, Serena Catania, Marco Fiore, Carlo Morosi and Luigi Mariani

      Version of Record online: 27 OCT 2009 | DOI: 10.1002/cncr.24695

      • original image
      • original image
      • original image

      This study investigated the effects of symptom interval in a large series of pediatric patients with soft tissue sarcomas, showing that symptom interval was associated with the patient's age and the size, site, and histological subtype of the tumor, and that longer intervals negatively influenced survival, in particular in the case of rhabdomyosarcoma.

    19. You have free access to this content
      Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate (pages 184–192)

      Jonathan C. Trent, Shalin S. Patel, Jianhu Zhang, Dejka M. Araujo, Juan-Carlos Plana, Daniel J. Lenihan, Dominic Fan, Shreyaskumar R. Patel, Robert S. Benjamin and Aarif Y. Khakoo

      Version of Record online: 2 NOV 2009 | DOI: 10.1002/cncr.24683

      • original image
      • original image
      • original image
      • original image

      Cardiotoxicity caused by imatinib mesylate in gastrointestinal stromal tumor and other sarcoma patients is uncommon and manageable, and should not be a reason to withhold imatinib mesylate therapy from cancer patients who would derive benefit. However, the long-term effects of imatinib mesylate on cardiac function remain unknown, and in vitro and in vivo studies support the notion that imatinib mesylate remains a potential cardiotoxin.

    20. Discipline

      Disparities Research
      You have free access to this content
      Disparities in medical care among commercially insured patients with newly diagnosed breast cancer : Opportunities for intervention (pages 193–202)

      Louise J. Short, Maxine D. Fisher, Peter M. Wahl, Monique B. Kelly, Grant D. Lawless, Sandra White, Nancy A. Rodriguez, Vincent J. Willey and Otis W. Brawley

      Version of Record online: 28 OCT 2009 | DOI: 10.1002/cncr.24691

      • original image

      Disparities in medical care for newly diagnosed breast cancer were evident between African-American women and white women despite commercial health plan insurance coverage. Interventions that address the gaps identified are needed.

    21. Epidemiology
      You have free access to this content
      Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma (pages 203–209)

      Robert R. McWilliams, Gloria M. Petersen, Kari G. Rabe, Leonard M. Holtegaard, Pamela J. Lynch, Michele D. Bishop and W. Edward Highsmith Jr

      Version of Record online: 2 NOV 2009 | DOI: 10.1002/cncr.24697

      • original image

      In a case-control study, the authors comprehensively tested for 39 known CFTR mutations in 949 patients and 13,340 controls. They found an increased risk of pancreatic adenocarcinoma associated with CFTR carrier status (odds ratio [OR], 1.40; P = .027) that was even more marked among patients who were younger at diagnosis (OR, 1.82; P = .01).

    22. Medical Oncology
      You have free access to this content
      Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients (pages 210–215)

      Stephen Sonis, Nathaniel Treister, Sant Chawla, George Demetri and Frank Haluska

      Version of Record online: 27 OCT 2009 | DOI: 10.1002/cncr.24696

      • original image
      • original image
      • original image

      Mammalian target of rapamycin inhibitor-associated stomatitis (mIAS) differed in behavior, appearance, and associated toxicities from mucositis induced by cytotoxic chemotherapy. The results from this study indicated that the similarity between mIAS and aphthous stomatitis may be the basis for an effective approach to its prevention and treatment.

    23. Pediatric Oncology
      You have free access to this content
      Inflammatory myofibroblastic tumors in childhood : A report from the Italian Cooperative Group studies (pages 216–226)

      Rita Alaggio, Giovanni Cecchetto, Gianni Bisogno, Claudio Gambini, Maria Luisa Calabrò, Alessandro Inserra, Renata Boldrini, Gian Luca De Salvo, Emanuele S. G. d'Amore and Patrizia Dall'Igna

      Version of Record online: 22 OCT 2009 | DOI: 10.1002/cncr.24684

      • original image
      • original image
      • original image
      • original image
      • original image

      Inflammatory myofibroblastic tumors (IMTs) are myofibroblastic lesions with unpredictable biologic behavior that occur in children and young adults. For this report, the authors investigated clinicopathologic features in a series of pediatric IMTs with the objective of identifying morphologic/immunohistochemical prognostic markers.

    24. You have free access to this content
      Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia (pages 227–232)

      Kristine R. Crews, Yinmei Zhou, Jennifer L. Pauley, Scott C. Howard, Sima Jeha, Mary V. Relling and Ching-Hon Pui

      Version of Record online: 15 OCT 2009 | DOI: 10.1002/cncr.24681

      • original image

      Plasma methotrexate clearance in pediatric patients with newly diagnosed acute lymphoblastic leukemia was found to be significantly lower in patients who received concomitant allopurinol versus nonrecombinant or recombinant urate oxidase during high-dose methotrexate administration. A higher proportion of patients in the allopurinol group had elevated methotrexate plasma concentrations and experienced mucositis after methotrexate treatment compared with patients in the urate oxidase group.

    25. You have free access to this content
      Aggressive fibromatosis in children and adolescents : The Italian experience (pages 233–240)

      Cristina Meazza, Gianni Bisogno, Alessandro Gronchi, Marco Fiore, Giovanni Cecchetto, Rita Alaggio, Giuseppe M. Milano, Michela Casanova, Modesto Carli and Andrea Ferrari

      Version of Record online: 30 NOV 2009 | DOI: 10.1002/cncr.24679

      The authors retrospectively analyzed a series of 94 children and adolescents with aggressive fibromatosis (AF). The results suggested that these tumors may have much the same natural history as AF adults. Interesting responses to systemic treatments were observed, particularly to low-dose chemotherapy.

    26. Radiation Oncology
      You have free access to this content
      Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy (pages 241–250)

      Samuel Bral, Michaël Duchateau, Harijati Versmessen, Douwe Verdries, Benedikt Engels, Mark De Ridder, Koen Tournel, Christine Collen, Hendrik Everaert, Denis Schallier, Jacques De Greve and Guy Storme

      Version of Record online: 13 NOV 2009 | DOI: 10.1002/cncr.24732

      • original image
      • original image
      • original image

      In this phase 1/2 trial, the authors assessed the possibility of radiation dose escalation using helical tomotherapy in a concurrent approach for unselected patients with inoperable, locally advanced nonsmall cell lung cancer. The maximum tolerated dose was set at 67.2 grays, and cisplatin/docetaxel was given weekly, resulting in an acceptable acute and late toxicity profile with a 61% response rate.

    27. Symptom Control and Palliative Care
      You have free access to this content
      An animal model for chemotherapy-associated steatohepatitis and its prevention by the oral administration of fatty acid bile acid conjugate (pages 251–255)

      Daniel Keizman, Natalie Maimon, Maya Ish-Shalom, Dana Buchbut, Moshe Inbar, Baruch Klein, Joelle Bernheim, Ilana Goldiner, Alicia Leikin-Frenkel and Fred Konikoff

      Version of Record online: 4 NOV 2009 | DOI: 10.1002/cncr.24710

      • original image
      • original image

      The current study indicates that C57BL/6 receiving weekly intraperitoneal injections of oxaliplatin at a dose of 6 mg/kg up to a total dose of 24 mg/kg could be used as a model for chemotherapy-associated steatohepatitis (CASH). Oral fatty acid bile acid conjugate therapy reduced the development of CASH in animals that were treated with oxaliplatin.

  6. Correspondence

    1. Top of page
    2. CancerScope
    3. Editorial
    4. Original Articles
    5. Original Article
    6. Original Articles
    7. Correspondence
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content
    5. You have free access to this content

SEARCH

SEARCH BY CITATION